Natalia Bilan, MD
Family Medicine · Rancho Santa Margarita, CANPI 1376644377
Payments from drug & device makers
Across 339 payments — averaging $27.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- AbbVie$2K
- Lilly USA, LLC$857
- GSK$790
- Merck$300
- Johnson & Johnson$289
- plus $3K from 33 others
What the payments were for
- Food & beverage$9,450100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $2,579 |
| AbbVie(2 entities) | 55 | $1,585 |
| Lilly USA, LLC | 29 | $857 |
| GSK | 26 | $790 |
| Merck | 17 | $300 |
| Johnson & Johnson | 5 | $289 |
| Amarin Pharma, Inc. | 13 | $275 |
| Amgen | 13 | $275 |
| Exact Sciences | 7 | $273 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $266 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $238 |
| Pfizer | 9 | $214 |
| Novo Nordisk | 7 | $160 |
| Idorsia Pharmaceuticals US Inc | 3 | $158 |
| Kowa Pharmaceuticals America, Inc. | 7 | $150 |
| Eisai Inc. | 7 | $123 |
| Biogen | 1 | $89 |
| Therapeuticsmd, Inc. | 5 | $89 |
| Abbott | 3 | $80 |
| Medtronic | 1 | $59 |
| IBSA Pharma Inc. | 3 | $57 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| Hologic Sales And Service, LLC | 3 | $52 |
| Sanofi Pasteur Inc. | 2 | $49 |
| Ironwood Pharmaceuticals, Inc | 2 | $48 |
| Astellas Pharma US Inc | 2 | $40 |
| Lucid Diagnostics Inc. | 2 | $39 |
| Tolmar, Inc. | 1 | $33 |
| Edwards Lifesciences | 1 | $29 |
| Averitas Pharma Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Agile Therapeutics, Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Icad, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$485
- BREZTRI$357
- FARXIGA$333
- AIRSUPRA$329
- NURTEC ODT$125
- AREXVY$125
- QUVIVIQ$122
- XARELTO$121
- MOUNJARO$120
- The Cologuard Plus Collection Kit$119
How this compares
$9,462 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $78,988 |
| MounjaroTirzepatide | 48 | $75,403 |
| JardianceEmpagliflozin | 46 | $64,769 |
| EliquisApixaban | 60 | $55,993 |
| FarxigaDapagliflozin Propanediol | 31 | $33,913 |
| MyrbetriqMirabegron | 38 | $27,374 |
| JanuviaSitagliptin Phosphate | 21 | $26,163 |
| LinzessLinaclotide | 25 | $20,409 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $18,952 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $13,433 |
| EntrestoSacubitril/Valsartan | 18 | $12,095 |
| Rosuvastatin Calcium | 409 | $5,915 |
| Roflumilast | 26 | $4,955 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $4,078 |
| Omega-3 Acid Ethyl Esters | 29 | $3,710 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $160 | $78,98875 claims |
| Lilly USA, LLCMounjaro | $857 | $75,40348 claims |
| PfizerEliquis | $214 | $55,99360 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,579 | $52,86550 claims |
| Astellas Pharma US IncMyrbetriq | $40 | $27,37438 claims |
| MerckJanuvia | $300 | $26,16321 claims |
| AbbVieLinzess, Synthroid | $1,585 | $21,66237 claims |
| GSKTrelegy Ellipta | $790 | $13,43316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Rancho Santa Margarita
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.